CN1546528A - Fusion protein of kininogen D5 and tumor necrosis factor related apoptosis-inducing ligand(D5-TRAIL), its preparation and use thereof - Google Patents
Fusion protein of kininogen D5 and tumor necrosis factor related apoptosis-inducing ligand(D5-TRAIL), its preparation and use thereof Download PDFInfo
- Publication number
- CN1546528A CN1546528A CNA2003101092657A CN200310109265A CN1546528A CN 1546528 A CN1546528 A CN 1546528A CN A2003101092657 A CNA2003101092657 A CN A2003101092657A CN 200310109265 A CN200310109265 A CN 200310109265A CN 1546528 A CN1546528 A CN 1546528A
- Authority
- CN
- China
- Prior art keywords
- fusion rotein
- trail
- sequence
- gly
- dna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Landscapes
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention provides the Kininogen D5-TRAIL fusion protein, the DNA sequence coding the fusion protein, carrying agent containing the DNA sequence, host cells containing the carrier, process for preparing the fusion protein through genetic engineering, and medicinal composition containing the fusion protein. The Kininogen D5-TRAIL fusion protein according to the invention can be applied into the preparation of medicament for treating diseases such as tumor.
Description
Technical field
The present invention relates to DNA recombinant technology and pharmaceutical field.More specifically, the present invention relates to the fusion rotein of people's prokinin the 5th structural domain (Kininogen D5) and apoptosis induction ligand related to human tumor necrosis factor (hereinafter to be referred as TRAIL), the encode dna sequence dna of this fusion rotein, the carrier that contains this dna sequence dna, the host cell that contains this carrier, prepare the method for this fusion rotein with genetically engineered, and this fusion rotein is as the application in the disease treatments such as tumour.
Background technology
Prokinin (Kininogen) is found existing so far recent two decades, and its major function is an anticoagulation, so all play a significant role in fibrinolytic, thrombus disease, inflammation etc.People's prokinin is made up of 644 amino acid, aminoacid sequence is seen GenBank No.:ABB59550, the product of its coded by said gene is under the effect of kallikrein, excise one of them structural region (being D4), remaining D1,2,3 and D5,6 connect into prokinin (being Kininogen) by a disulfide linkage, nucleotide sequence is seen GenBank No.:AH005302.In recent years find that it has antineoplastic action (mainly concentrating on Kininogen D5 part), protein [Blood, 2000 that the N-that has proved prokinin holds 402-626 amino acids (being the 24-248 amino acids of Kininogen D5) or partial sequence wherein to form; 95 (2): 543-550], or polypeptide [Arterioscler Thromb Vasc Biol, 2001; 21 (9): 1427-1433] propagation that can be by suppressing endotheliocyte, move and induce its apoptosis and produce the tumor neovasculature effect that suppresses in vivo, thereby have anti-tumor function.
Nineteen ninety-five, external report is expressed sequence label library (expressed sequence tag from the people, EST) screen a kind of gene of the anti-tumor protein matter of encoding in, the protein of this genes encoding is called tumor necrosin relative death inducing ligand (tumor necrosis factor-related apoptosis-inducing ligand, TRAIL), claim Tumor wilting extract (apoptotin-2 ligand again, be called for short Apo-2L), be tumour necrosis factor (tumor necrosisfactor, TNF) one of family member, it is by starting cell inherent apoptosis program, induced tumor and transformant apoptosis effectively, and normal cell is not had influence.The code sequence of people's trail dna is shown 843 Nucleotide (SEQ ID NO.3), and nucleotide sequence is seen GenBank No.:NM_003810, and encoded protein matter TRAIL forms (SEQ ID NO.4) by 281 amino acid.Proved already that TRAIL was typical II type transmembrane protein, its N-holds the extracellular region of the 95th or 114 beginning can form free solubility tumor apoptosis fibroin, has the tumor death effect equally.This gene can obtain from biotech company (http://www.invivogen.com) at present.
Because Kininogen D5 acts on different links with TRAIL to suppressing tumor growth, with suitable amino acid connecting arm [Protein Eng, 2003; 15 (11): 871-879] make both amalgamation and expressions, the recombinant fusion protein that is produced both can suppress tumour by the TRAIL inducing apoptosis of tumour cell thus, can also be antitumor by Kininogen D5 inhibition endothelial cells in tumor neogenetic blood vessels growth.Therefore, the resulting fused protein of the present invention can strengthen antineoplastic effect down both collaborative, also can reduce both respectively administration give trouble and the misery that the patient brought, for treatment of diseases such as antitumor provides new medicine or preparation.Therefore, this area presses for that exploitation is new to have Kininogen D5 and a bioactive medicine of TRAIL.In addition, this area also presses for cheap and or the easy production technique of step of cost of development.
Summary of the invention
One object of the present invention just provides a kind of new have Kininogen D5 and the bioactive medicine of TRAIL, and it is the fusion rotein of Kininogen D5 and TRAIL.
Another object of the present invention provide encoding said fusion protein DNA, contain the carrier of this dna sequence dna, contain the host cell of this carrier.
Another object of the present invention provide a kind of with low cost and or the method for the easy described KininogenD5-TRAIL fusion rotein of production of step.
In a first aspect of the present invention, a kind of fusion rotein is provided, it comprises:
(a) prokinin the 5th structural domain element, this element has the aminoacid sequence of people's prokinin the 5th structural domain or its active fragments;
(b) tumor necrosin relative death inducing ligand element, this element has the aminoacid sequence of apoptosis induction ligand related to human tumor necrosis factor or its active fragments; And
(c) 1-20 between prokinin the 5th structural domain element and tumor necrosin relative death inducing ligand element amino acid whose catenation sequence.
Better, described prokinin the 5th structural domain element has the aminoacid sequence of 1-266 position, 24-153 position or 60-148 position among the SEQ ID NO.2;
Described tumor necrosin relative death inducing ligand element has the aminoacid sequence of 1-281 position, 95-281 position, 114-281 position among the SEQ ID NO.4;
And described catenation sequence is for containing 4-10 amino acid whose joint peptide.
Better, described fusion rotein comprises the aminoacid sequence shown in the SEQ ID NO.6.
In a second aspect of the present invention, provide a kind of isolated DNA molecule, the fusion rotein that the invention of its code book is above-mentioned.Preferably, described dna molecule encode comprises the fusion rotein of the aminoacid sequence shown in the SEQ ID NO.6.Better, described dna molecular comprises the nucleotide sequence shown in the SEQ ID NO.5.
In a third aspect of the present invention, carrier that contains above-mentioned dna molecular and the host cell that contains above-mentioned carrier are provided.
In a fourth aspect of the present invention, a kind of method that produces fusion rotein of the present invention is provided, it comprises step:
Under the condition that is fit to the described fusion rotein of expression, cultivate above-mentioned host cell, thereby give expression to described fusion rotein; With separate described fusion rotein.
In a fifth aspect of the present invention, a kind of pharmaceutical composition is provided, it comprises pharmaceutically acceptable carrier or vehicle or thinner, and the fusion rotein of the present invention of significant quantity.
In a sixth aspect of the present invention, the purposes of fusion rotein of the present invention is provided, it is used to prepare the medicine for the treatment of tumour.
Description of drawings
Fig. 1 has shown the different connecting methods of Kininogen D5, amino acid connecting arm and the TRAIL of different lengths.Wherein:
Expression: TRAIL aminoacid sequence;
Expression: Kininogen D5 aminoacid sequence;
Expression: amino acid connecting arm sequence;
Expression: disappearance partial amino-acid.
Fig. 2 has shown the electrophoretic analysis (SDS-PAGE) of the recombinant expressed and purge process of a kind of distinctive KininogenD5-TRAIL fusion rotein.A wherein: molecular weight protein marker; B: the broken supernatant of Kininogen D5-TRAIL engineering bacteria that protokaryon reorganization thermal induction is expressed; C: the active peak of the reorganization KininogenD5-TRAIL fused protein of metal affinity purification; D: the affine elutant of metal; E: the kininogenD5-TRAIL that is further purified; F: ammonium sulfate precipitation is expressed the active ingredient of supernatant; G: the bacteria breaking supernatant before the abduction delivering Kininogen D5-TRAIL.
Embodiment
The inventor merges Kininogen D5 gene and trail dna through extensive and deep research, produces the fusion rotein of the Kininogen D5-TRAIL that is connected by suitable amino acid connecting arm.Described fused protein has both biological functions, both can be antitumor by Kininogen D5 N-end inhibition endothelial cells in tumor neogenetic blood vessels growth, can also suppress tumour by the TRAIL inducing apoptosis of tumour cell.Therefore, the resulting Kininogen D5-TRAIL of the present invention fused protein can strengthen antineoplastic effect down both collaborative, also can reduce both respectively administration give trouble and the misery that the patient brought, for treatment such as antitumor provides new compound.Finished the present invention on this basis.
Definition
As used herein, term " fusion rotein of prokinin the 5th structural domain and tumor necrosin relative death inducing ligand ", " Kininogen D5-TRAIL fusion rotein " etc. are used interchangeably, all refer to merge the albumen that forms by the aminoacid sequence of prokinin the 5th structural domain element and the aminoacid sequence of tumor necrosin relative death inducing ligand element, wherein between can have or not have the connection peptides sequence.In addition, described fusion rotein can have or not have initial methionine(Met) or signal peptide.
As used herein, " prokinin the 5th structural domain element " refers to a part of aminoacid sequence in described fusion rotein in the term fusion rotein, this sequence has substantially the same aminoacid sequence with total length prokinin the 5th structural domain or its active fragments natural or variation, and has and the substantially the same biological activity of natural prokinin the 5th structural domain.Preferred prokinin the 5th structural domain element is people's prokinin the 5th structural domain, and more preferably people's prokinin the 5th structural domain or its active fragments of total length are as the aminoacid sequence of 1-266 position, 24-153 position or 60-148 position among the SEQ ID NO.2.
As used herein, " tumor necrosin relative death inducing ligand element " or " TRAIL element " is used interchangeably in the term fusion rotein, the a part of aminoacid sequence of finger in described fusion rotein, this sequence has substantially the same aminoacid sequence with total length tumor necrosin relative death inducing ligand or its active fragments natural or variation, and has the biological activity substantially the same with natural tumor necrosin relative death inducing ligand.Preferred TRAIL element is an apoptosis induction ligand related to human tumor necrosis factor, the more preferably tumor necrosin relative death inducing ligand of total length or its active fragments are as the aminoacid sequence of 1-281 position, 95-281 position, 114-281 position among the SEQ ID NO.4.
The sequence of prokinin the 5th structural domain and tumor necrosin relative death inducing ligand can be derived from the people, also can be derived from inhuman animal.Yet, people's native sequences preferably.
As used herein, term " connection peptides " or " amino acid connecting arm " are used interchangeably, and refer to small peptide or amino acid between the aminoacid sequence of the aminoacid sequence of prokinin the 5th structural domain element and TRAIL element, that play ligation.The length of connection peptides is generally 1-20 amino acid, preferably is 3-10 amino acid, is 4-6 amino acid best.The technician can be according to this area ordinary method [as referring to PNAS 1998; 95:5929-5934; Protein Eng, 2000; 13 (5): 309-312; Protein Eng, 2003; 15 (11): documents such as 871-879] design connection peptides.Usually, connection peptides does not influence or the aminoacid sequence that has a strong impact on the aminoacid sequence of prokinin the 5th structural domain element and TRAIL element forms correct folding and space conformation.
Preferred connection peptides example comprises (but being not limited to): becoming separate structural domain in order to help protein folding, is suitable (170-181 position among the SEQ ID NO.6) with sequences such as SGGGGSGGGG as connecting arm; In order to help proteolytic enzyme Kininogen D5-TRAIL is cut into two independently protein moleculars, the restriction enzyme site of the available active X factor (IEGR) connects arm, similar, chymotrypsin 1, papain, plasmin, thrombin, the restriction enzyme site of trypsin etc. also can design as the amino acid connecting arm; In order to help purifying, can be 6His as connecting arm, to use metal affinity chromatography purifying Clareticulin-TRAIL fusion rotein; The combination of above-mentioned three kinds of schemes also can be designed to new amino acid connecting arm, has merged protease cutting site (NIa proteolytic enzyme) and metal affinity chromatography site 6His exactly as the NVVVHQAHHHHHHEFTYK connecting arm.
The dna sequence dna of code book invention fusion rotein, all synthetic.Also available pcr amplification or synthetic method obtain prokinin the 5th structural domain and or the DNA sequences encoding of tumor necrosin relative death inducing ligand, then it is stitched together, form the dna sequence dna of code book invention fusion rotein.
Having obtained it to be connected into suitable expression vector after code book invents the dna sequence dna of new fusion rotein, change proper host cell again over to.At last, cultivate the host cell after transforming, obtain new fusion rotein of the present invention by separation and purification.
As used herein, term " carrier " comprises plasmid, clay, expression vector, cloning vector, virus vector etc.Representational state comprises (but being not limited to): the carrier that can express in eukaryotic cells such as eukaryotic cell such as CHO, COS series, the carrier that can express in yeast saccharomyces cerevisiae or pichia yeast can be at the carrier and the prokaryotic expression carrier of expressed in insect cells such as silkworm.
In the present invention, can select various carrier known in the art such as commercially available carrier for use.Such as, select commercially available carrier for use, the nucleotide sequence of then code book being invented new fusion rotein operationally is connected in expression regulation sequence, can form protein expression vector.
As used herein, " operationally being connected in " refers to a kind of like this situation, and promptly some part of linear DNA sequence can influence the activity of same other parts of linear DNA sequence.For example, if signal peptide DNA as precursor expression and participate in the secretion of polypeptide, signal peptide (secretion leader sequence) DNA operationally is connected in polypeptid DNA so; If transcribing of promotor control sequence, it is operationally to be connected in encoding sequence so; When if ribosome bind site is placed in the position that can make its translation, it is operationally to be connected in encoding sequence so.Generally, " operationally being connected in " means adjoining, then means in reading frame adjacent for the secretion leader sequence.
In the present invention, term " host cell " comprises prokaryotic cell prokaryocyte and eukaryotic cell.The example of prokaryotic host cell commonly used comprises intestinal bacteria, Bacillus subtilus etc.Eukaryotic host cell commonly used comprises yeast cell, insect cell and mammalian cell.Preferable, this host cell is an eukaryotic cell, more preferably bombyx mori cell.
After obtaining transformed host cells, can under the condition that is fit to expression fusion rotein of the present invention, cultivate this cell, thereby give expression to fusion rotein.Can utilize its physics, the separating by various separation methods with other characteristic and the albumen of purification of Recombinant of chemistry.These methods are well-known to those skilled in the art.The example of these methods comprises (but being not limited to): conventional renaturation handles, handle the combination of (salt analysis method), centrifugal, the broken bacterium of infiltration, supersound process, super centrifugal, sieve chromatography (gel-filtration), adsorption chromatography, ion exchange chromatography, high performance liquid chromatography (HPLC) and other various liquid chromatography (LC) technology and these methods with protein precipitant.
Kininogen D5-TRAIL fusion rotein of the present invention had both had the function of the inhibition endothelial cells in tumor neogenetic blood vessels growth of Kininogen D5, had the effect of the inducing apoptosis of tumour cell of TRAIL again.
In another aspect of this invention, also provide a kind of pharmaceutical composition.Pharmaceutical composition of the present invention comprises the of the present invention novel Kininogen D5-TRAIL fusion rotein of significant quantity, and at least a pharmaceutically acceptable carrier, thinner or vehicle.In preparation during these compositions, usually with activeconstituents and mixed with excipients, or with the vehicle dilution, or wrap in the carrier that exists with capsule or anther sac form.Do the time spent when vehicle plays thinner, it can be solid, semisolid or the fluent material medium as vehicle, carrier or activeconstituents.Therefore, composition can be tablet, pill, pulvis, solution, syrup, sterilizing injecting solution etc.The example of suitable vehicle comprises: lactose, glucose, sucrose, sorbyl alcohol, N.F,USP MANNITOL, starch, Microcrystalline Cellulose, polyvinylpyrrolidone, Mierocrystalline cellulose, water, etc.Preparation also can comprise: wetting agent, emulsifying agent, sanitas (as methyl hydroxybenzoate and propyl ester), sweeting agent etc.
Composition can be made into unit or polynary formulation.Each formulation comprises the active substance that calculates predetermined amount in order to produce desired treatment effect, and the proper drug vehicle.
The pharmaceutical composition for preparing can carry out administration by conventional route, comprising (but being not limited to): intramuscular, intraperitoneal, intravenously, subcutaneous, intracutaneous, oral or topical.
When making pharmaceutical composition, be that fusion rotein of the present invention or its antibody with safe and effective amount is applied to the people, wherein this safe and effective amount is usually at least about 1 microgram/kg body weight, and in most of the cases being no more than about 8 mg/kg body weight, this preferable dosage is about 1 microgram/kg body weight-Yue 1 mg/kg body weight.Certainly, concrete dosage also should be considered factors such as route of administration, patient health situation, and these all are within the skilled practitioners skill.
In addition, fusion rotein of the present invention also can with the other treatment drug combination, comprising (but being not limited to): various cytokines, as IFN, TNF, IL-2 etc.; Various tumor chemotherapeutic drugs, influence biological nucleic acid synthetic medicine as 5-Fu, methotrexate etc., alkylating agent such as mustargen, endoxan class, Zorubicin, dactinomycin etc. disturb transcription to stop RNA synthetic medicine, and vincristine(VCR), camptothecin influence various kinds of drug such as the medicine of protein synthesis and some hormone.
In sum, major advantage of the present invention is as follows:
(1) Kininogen D5-TRAIL fusion rotein had both had the function of the inhibition endothelial cells in tumor neogenetic blood vessels growth of Kininogen D5, had the effect of the inducing apoptosis of tumour cell of TRAIL again, was a kind of newtype drug for the treatment of tumour.
(2) convenient drug administration.Because both useful effect dosage is in most of the cases approaching, so give simultaneously with fusion rotein, has made things convenient for the proportioning of single medicine, the experimenter has also reduced misery simultaneously.
(3) has target.Kininogen D5 can transport TRAIL to tumor by local in the tumor neovasculature while of inhibition and play a role; Same, when TRAIL acted on tumour cell, the new vessel that Kininogen D5 is transported to tumor tissues was brought into play its restraining effect.
(4) strengthen proteic stability.Behind both amalgamation and expressions, vitro half-lives is obviously elongated, and the stability in the aqueous solution is become one or two month (all under 4 ℃) after the fusion each about week by both; Believe the prolongation that in vivo transformation period also can be suitable.
Below in conjunction with specific embodiment, further set forth the present invention.Should be understood that these embodiment only to be used to the present invention is described and be not used in and limit the scope of the invention.The experimental technique of unreceipted actual conditions in the following example, usually according to normal condition, people such as Sambrook for example, molecular cloning: laboratory manual (New York:ColdSpring Harbor Laboratory Press, 1989) condition described in, or the condition of advising according to manufacturer.
Embodiment 1
Set up the cDNA library, screening obtains TRAIL and Kininogen D5 gene
1. prepare the total RNA of human peripheral blood single nucleus cell
Use lymphocyte separation medium separation of human peripheral blood lymphocyte routinely, with RPMI-1640 substratum (GIBCO company), adding 10% newborn calf serum (Hangzhou folium ilicis chinensis biotech firm) and penicillin and Streptomycin sulphate is cultured to adherent, get mononuclearcell, intracellular toxin with the intestinal bacteria R595 of 10 μ g/L stimulates 2h then, to activate mononuclearcell, collect 10
7Cell with total RNA extraction agent box (Qiagen company) extracted total RNA, gets the total RNA of human peripheral blood single nucleus cell.
2. set up the cDNA library, the screening trail dna
Total RNA of above-mentioned gained, get total mRNA with Oligo-dT post (Qiagen company) purifying, carry out the synthetic of cDNA first chain and second chain with cDNA synthetic agent box (Clontch company) by specification, be connected in the λ gt10 carrier after adding EcoR I joint, and be packaged into the lambda particles phage library with lambda particles phage package kit (Clontech company), build up λ gt10 cDNA library, the titre in library is 6 * 10
6
This λ gt10 cDNA library is with 1 * 10
5Bed board on bacterium colony/LB flat board is manufactured the multiple die on the nitrocellulose filter of 20 * 20cm.With the theoretical sequences Design random primer of TRAIL, preparation gene probe, screening by hybridization library.The repetition die that contains bacterium colony is containing 10% T 500,100 μ g/ml tRNA and 6 * 10
565 ℃ of hybridization are spent the night in the plate screening damping fluid of cpm/ml probe (50mmol/L Tris-HCl pH7.5,1mol/L NaCl, 0.1% trisodium phosphate, 0.2% polyvinylpyrrolidone and 0.2%Ficoll).65 ℃ of plate screenings, and 2 * SSC (0.3mol/L NaCl, the 30mmol/L Trisodium Citrate, pH7.0), the 0.1%SDS damping fluid washes twice.Closely contact with film at-40 ℃ then, screened 40 hours.
Double male sample is chosen corresponding bacterium colony from main flat board, forwards the damping fluid (100mmol/L NaCl, the 10mmol/L MgSO that have added gelatin to
4, 50mmol/L Tris-HCl, on LB flat board pH7.5), obtain 12 positive plaques.The λ DNA of 12 purifying digests with Not I, 1% agarose gel electrophoresis, and the Southern trace is confirmed and probe hybridization.When selecting with above-mentioned probe hybridization, the clone of radioactive intensity maximum (about 1.7kp) carries out the DNA purifying.These clones' insertion portion is by the Not I site of subclone to pSPORT1 (GIBCO company).Measure the dna sequence dna of insertion portion in the plasmid.From the result of sequential analysis, obtain, insertion sequence in one of them plasmid is 1769bp, 5 ' the non-translational region that comprises 87bp, 843bp open reading frame and 3 ' non-translational region (contain polyadenylation signal or claim the polyA tail), this fragment is a trail dna, encoding sequence wherein such as SEQ ID NO.3.According to the translation initiation site requirement of Kozak definition, 88-90 position Nucleotide (ATG, coding methionine(Met)) is translation initiation site, 281 aminoacid sequences that the maximum open reading frame that obtains thus is coded such as SEQ ID NO.4.
3. screen Kininogen D5 gene
With step 1 and 2 similar methods, screening obtains the encoding sequence such as the SEQ ID NO.1 of Kininogen D5 gene from people myocardial cell cDNA library, coded 266 aminoacid sequences such as the SEQ IDNO.2 of deduction.
Embodiment 2
Reverse transcription polymerase chain reaction method (being RT-PCR) obtains the encoding sequence of Kininogen D5
1.RT obtain Kininogen D5 cDNA first chain
With the total RNA of people myocardial cell from Clontech company (U.S.) purchase is template, is primer with P1, and Kininogen D5 cDNA first chain is synthesized in reversed transcriptive enzyme catalysis.
2. polymerase chain reaction (PCR) amplification obtains Kininogen D5 encoding sequence
With above-mentioned cDNA first chain is template, and P1, P2 are primer, the synthetic and amplification Kininogen D5 encoding sequence of Tag archaeal dna polymerase catalysis.Through sequential analysis, the shown Kininogen D5 encoding sequence of the sequence (GenBank No.:AH005302) of gained dna sequence dna and GenBank registration is consistent, has promptly obtained Kininogen D5 coding nucleotide sequence.Primer:
P1：CTG?TTTA?GAT?CTC?ACT?GAT?G(SEQ?ID?NO.30)
P2：AGA?AAT?ACC?CAT?AGC?CAC(SEQ?ID?NO.31)
Embodiment 3
RT-PCR obtains the encoding sequence of TRAIL
1. prepare the total RNA of human peripheral blood single nucleus cell
(1) isolated lymphocytes from human peripheral according to a conventional method, and then obtain mononuclearcell with adherent method;
(2) activate the abundance that mononuclearcell is expressed more gene with irritation cell and improved RNA with bacterial endotoxin, with RNA extraction agent box (Qiagen company) extracted total RNA.
2. reverse transcription (RT) obtains TRAIL cDNA first chain
With above-mentioned total RNA is template, is primer with P3, and TRAIL cDNA first chain is synthesized in reversed transcriptive enzyme catalysis.
3. polymerase chain reaction (PCR) amplification obtains the TRAIL encoding sequence
With above-mentioned cDNA first chain is template, and P3, P4 are primer, the synthetic and amplification TRAIL encoding sequence of Tag archaeal dna polymerase catalysis.Through sequential analysis, the shown TRAIL encoding sequence of the sequence (NM_003810) of gained dna sequence dna and GenBank registration is consistent, has promptly obtained the TRAIL coding nucleotide sequence
P3：GAC?TTA?CAG?CAG?TCA?GAC?TCT?GAC(SEQ?ID?NO.32)
P4：TAT?TGC?TTT?TTC?TTT?CCA?GGT?CAG(SEQ?ID?NO.33)
Embodiment 4
Construction expression Kininogen D5-TRAIL fused protein expression vector
PBV220 with reconstruction is carrier (original plasmid is so kind as to give by Inst. of Viruses, China Preventive Medicine Science Academy), the recombinant plasmid of construction expression TRAIL 114-281 amino acids, the prokaryotic expression carrier of constructed expression TRAIL 114-281 amino acids, called after pBV-TRAIL.The recombinant expressed of corresponding fusion proteins of the present invention implemented with same method.Concrete implementation step is as follows:
1. design and synthesize primer and oligonucleotide two strands
Primer P5, the P6 of design amplification coding TRAIL 114-281 amino acids, its sequence is:
P5：5′-AC
G?AAT?TCA?CA
A?TGG?TGA?GAG?AAA?GAG?GTC-3′(SEQ?ID?NO.34)；
P6：5′-AC
G?GAT?CCT?TAG?CCA?ACT?AAA?AAG-3′(SEQ?ID?NO.35)
The distance that P5 has optimized between SD sequence and the foreign gene is 8 Nucleotide (italicized item), introduces synthetic initiator codon ATG of albumen and EcoR I restriction enzyme site GAATTC; P6 introduces BamH I restriction enzyme site GGATCC.
Synthetic oligonucleotide two strands, sequence following (not providing the sequence of complementary strand):
P7：5′-AA
A?GAT?CTC?TCA?CCT?ACC?AAA?CAA?TGC?CCC?CCT?GCA?AAA?AAT
AAA?TTC?ATA?TAA?AAA?ACA?TAC?AGA?TAA?CCA?TCT?GCG?GTG?ATA?AAT?TAT
CTC?TGG?CGG?TGT?TGA?CAT?AAA
C?TGA?GCA?CAT?CAG
CAG?GAC?GCA?CTG?ACC?ACC?ATG?AAG?GTG?ACG?CTC?TTA?AAA?ATT?AAG?CCC
TGA?AGA?AGG?GCA?GCA?TTC?AAA?GCA?GAA?GGC?TTT?GGG?GTG?TGT?GAT?ACG?AAA
CGA?AGC?ATT?GGT?TAA?AAA?TTA?AGG?AG
G?AAT?TCA?CA-3′(SEQ?ID?NO.36)
Wherein, the italicized item of P7 sequence is λ P
LP
RTandem promoter subsequence, dash area are cI arrestin binding site, and black matrix is the SD sequence for optimizing partly, and 5 ' end is introduced BglII restriction enzyme site AGATCT, and 3 ' end is introduced EcoR I restriction enzyme site GAATTC;
P8：5′-AA
G?GAT?CCG?TCG?ACC?TGC?AGC?CAA?GCT?TGG?CTG?TTT?TGG?CGGATG?AGA?
GAA?GAT?TTT?CAG-3′(SEQ?ID?NO.37)
Wherein, 5 of P8 sequence ' end has been introduced BamH I restriction enzyme site GGATCC, 3 ' introducing Xmn I restriction enzyme site GAANNNNTTC.
2. construction of expression vector pBV-TRAIL, specific as follows:
With P5, P6 is primer, is template with the trail dna of embodiment 3, pcr amplification trail dna encoding sequence, and product is cut (toolenzyme is all available from U.S. NEB company) with EcoR I and BamH I enzyme.Cut P3 with Bgl II and EcoR I enzyme, BamH I and Xmn I enzyme are cut P4.With Bgl II and Xmn I double digestion pBV220 plasmid.
Above-mentioned each endonuclease bamhi sepharose reclaims the fragment of corresponding size, connects each fragment with the T4 dna ligase, and resulting recombinant plasmid is the expression vector of Tumor wilting extract, called after pBV-TRAIL.
PBV-TRAIL compares pBV220 and has following feature: the TRAIL encoding gene is subjected to upstream lambda particles phage PLPR tandem promoter control, the ribosome binding sequence of optimizing (SD sequence), insert EcoR I restriction enzyme site and translation initiation codon ATG, optimized simultaneously and the SD sequence between distance be 8 Nucleotide; Insert BamH I restriction enzyme site etc. in Tumor wilting extract encoding gene downstream.This plasmid and pBV220 are same, contain the cIts857 binding sequence in promoter sequence; Have ampicillin resistance gene; Transcription termination sequence rrnB; Contain coding temperature sensitive protein factor cIts857 gene on the plasmid, this coded product inactivation in the time of 42 ℃, thus losing inhibition to promotor, the downstream foreign gene of promotor control is expressed.Feature nucleotide sequences such as the SD sequence of upstream regulatory sequence, optimization, TRAIL encoding sequence and translation termination sequence are shown in SEQ IDNO.7.
With above-mentioned same method, with the listed sequence of table 1 is primer (listed primer only part has been enumerated listed 18 kinds of fused proteins among amplification Fig. 1), corresponding gene with above-mentioned gained is a template, amplification corresponding encoded dna fragmentation, digestion with restriction enzyme, T4 dna ligase connect on the carrier that enzyme is cut equally, the transformed competence colibacillus cell, screening contains the clone of recombinant plasmid, and order-checking is identified and confirmed.
The tabulation of table 1 primer nucleotides sequence
First group: the Kininogen D5 in the coded fused protein that increases holds at N, and (p represents primer to A-I as shown in Figure 1, and K represents Kininogen D5, T represents TRAIL, sandwich digit is represented coded amino acid whose initial or final position, and f represents forward primer, and r represents reverse primer)
| ?pK1f | ?5′-gcg?aat?tca?cat?atg?aaa?agg?cct?cca?gg-3′ | SEQ?ID?NO.8 |
| ?pK24f | ?5′-gcg?aat?tca?tgg?taa?gtc?cac?ccc?aca?c-3′ | SEQ?ID?NO.9 |
| ?pK60f | ?5′-gcg?aat?tca?tga?aac?ata?atc?ttg?gcc?atg-3′ | SEQ?ID?NO.10 |
| ?pK148r | ?5′-aag?gat?ccg?ctt?gcc?aaa?tgc?tct?g-3′ | SEQ?ID?NO.11 |
| ?pK153r | ?5′-aag?gat?cca?ctg?tct?tca?gaa?gag?ctt?g-3′ | SEQ?ID?NO.12 |
| ?PK266r | ?5′-aag?gat?cca?gaa?agg?cca?tca?gtg?ag-3′ | SEQ?ID?NO.13 |
| ?pT1f | ?5′-aac?tgc?aga?tgg?cta?tga?tgg?agg?tc-3′ | SEQ?ID?NO.14 |
| ?pT95f | ?5′-aac?tgc?aga?cct?ctg?agg?aaa?cca?tt-3′ | SEQ?ID?NO.15 |
| ?pT114f | ?5′-aac?tgc?agg?tga?gag?aaa?gag?gtc?ctc-3′ | SEQ?ID?NO.16 |
| ?pT281r | ?5′-tca?agc?tta?gcc?aac?taa?aaa?ggc-3′ | SEQ?ID?NO.17 |
Second group: the TRAIL in the coded fused protein that increases holds at N, a-i as shown in Figure 1 (be first group of primer of difference, shown in add 1 after the primer title)
| ?pT1f1 | ?5′-gcg?aat?tca?cat?atg?gct?atg?atg?gag?gtc-3′ | SEQ?ID?NO.18 |
| ?pT95f1 | ?5′-gcg?aat?tca?cat?atg?acc?tct?gag?gaa?acc?att-3′ | SEQ?ID?NO.19 |
| ?pT114f1 | ?5′-gcg?aat?tca?cat?atg?gtg?aga?gaa?aga?gg-3′ | SEQ?ID?NO.20 |
| ?pT281r1 | ?5′-aag?gat?cca?act?aaa?aag?gcc?ccg-3′ | SEQ?ID?NO.21 |
| ?pK1f1 | ?5′-aac?tgc?aga?tga?aaa?ggc?ctc?cag?g-3′ | SEQ?ID?NO.22 |
| ?pK24f1 | ?5′-aac?tgc?agg?taa?gtc?cac?ccc?aca?c-3′ | SEQ?ID?NO.23 |
| ?pK60f1 | ?5′-aac?tgc?aga?aac?ata?atc?ttg?gcc?atg-3′ | SEQ?ID?NO.24 |
| ?pK148r1 | ?5′-tca?agc?tta?gct?tgc?caa?atg?ctc?tg-3′ | SEQ?ID?NO.25 |
| ?pK153r1 | ?5′-tca?agc?tta?act?gtc?ttc?aga?aga?gct?tg-3′ | SEQ?ID?NO.26 |
| ?pK266r1 | ?5′-tca?agc?tta?aga?aag?gcc?atc?agt?g-3′ | SEQ?ID?NO.27 |
The 3rd group: the encoding sequence of amino acid connecting arm can form double-stranded DNA through simple sex change and renaturation
| ?pL1 | ?5′-ga?tcc?ggc?gga?ggc?ggg?agc?ggc?ggg?ggc?gga?agc?ctg?ca-3′ | SEQ?ID?NO.28 |
| ?pL2 | ?5′-ggc?ttc?cgc?ccc?cgc?cgc?tcc?cgc?ctc?cgc?cg-3′ | SEQ?ID?NO.29 |
A series of recombinant plasmids of expressing different lengths Kininogen D5-TRAIL fused protein have respectively been obtained thus.Especially, the 18 kinds of KininogenD5-TRAIL recombinant fusion proteins as shown in Figure 1 that prepare with cited primer can directly show at external killing tumor cell, suppress the biological action of the tumor growth of transplanting in vivo.
A kind of nucleotide sequence of preferred expressing K ininogen D5-TRAIL fused protein is shown in SEQ IDNO.5, and the aminoacid sequence of being inferred is shown in SEQ ID NO.6.
Embodiment 5
Transformed into escherichia coli is set up engineering bacteria
Routinely with a series of recombinant expression plasmid transformed into escherichia coli BL21[genotype such as pBV-TRAIL that obtain among the embodiment 4: hsdS gal (λ cIts857ind1 Sam7 nin5 lacUV5-T7)] (can give birth to worker bio-engineering corporation) available from Shanghai, isolated plasmid dna from ammonia benzyl resistance bacterium colony, enzyme is cut evaluation, order-checking confirms that the positive colony of gained is the engineering bacteria of expressing the respective egg white matter.
Embodiment 6
Preparation Kininogen D5-TRAIL fused protein
Various substratum are as follows: the LB substratum is as the test tube seed culture, and 2 * YT substratum is cultivated as secondary seed, and semisynthetic medium is used for fermentation, and fed-batch adds to be cultivated.
LB culture medium prescription (g/L): peptone: yeast powder: NaCl=10: 5: 5;
2 * YT culture medium prescription (g/L): peptone: yeast powder: NaCl=16: 10: 5;
Prescription (g/L) in the semi-synthetic fermention medium: peptone: yeast powder: KH
2PO
4: K
2HPO
4: Na
2HPO
4.12H
2O: (NH
4)
2SO
4: NH
4Cl=5: 5: 2: 4: 7: 1.2: 0.2;
Various trace element solutions, concentration are (g/L): MnSO
4.5H
2O: CaCl
2.6H
2O: Na
2MoO
4.2H
2O: ZnCl
2: CuSO
4.5H
2O: H
3BO
4: FeSO
4.7H
2O: CaCl
2.2H
2O: MgSO
4.7H
2O=0.001: 0.004: 0.002: 0.002: 0.001: 0.0005: 0.02: 0.02: 0.3;
Feeding medium during fermentation prescription (g/L): glucose: yeast powder: peptone: MgSO
4.7H
2O=200: 70: 70: 5.7.
The pH value of substratum all is adjusted to 7.0.Add penbritin final concentration to 100 μ g/ml behind the various substratum high-temperature sterilizations.
After the first order seed overnight incubation, be forwarded to secondary seed with 1: 50 ratio, fermentor tank is gone into the secondary seed of overnight incubation by 5% inoculation of working volume.Cultivate and divide two stages to carry out, cultivated 5-7 hour for 32 ℃; Being warming up to 42 ℃ cultivated 4-5 hour.Constant flow pump adds feed supplement, and dissolved oxygen is controlled between the 30-50%.Obtain the wet thallus of about 20-30 grams per liter fermented liquid.
Ultrasonication fermentation thalline, the centrifuging and taking supernatant is crossed the filter membrane of 0.22 μ m; With NTA Supperflow (Qiagen company) or TALON Metal Affinity Rsins (Clontech company) row metal affinity chromatography, 10mmol/L imidazoles, pH7.0 wash-out foreign protein, again with the 100mmol/L imidazoles, pH7.0, wash-out recombinant protein; Elutriant is crossed the CM Mierocrystalline cellulose, collects active ingredient; Be further purified after Sephacryl S-200, can obtain highly purified recombination fusion protein.
The result: with a kind of fusion rotein shown in Fig. 1-i (is TRAIL
114-281-Kininogen D5
60-148) to carry out protokaryon recombinant expressed for example, constructed engineering bacteria is expressed through thermal induction, after the ultrasonication, the capable SDS-PAGE of the centrifugal isolating supernatant of institute, as seen expressed fusion protein accounts for more than 10% of supernatant total protein, and it is pure to reach electrophoresis after being further purified, and the results are shown in Figure 2.The calculating molecular weight is 30.6kD, and is consistent with theoretical value.The theoretical iso-electric point of inferring is 10.2.All the other independent TRAIL, Kininogen D5 or both can obtain similar results after merging abduction delivering, obtain the recombinant protein of corresponding molecular weight size.
Embodiment 7
The biologic activity of fused protein is determined
In the present embodiment, measure the active and Kininogen D5 activity of TRAIL that fusion rotein had.
The activity of TRAIL: external can human pancreas's cancerous ductal epithelial cell 1990 strain cells, the cell lung cancer NCI-460 of the National People's Congress, murine melanoma B16 etc. are target cell, determine the biologic activity of TRAIL, in the body with the human colon carcinoma HCT-8 transplanted tumor that suppresses nude mice etc. external to the TRAIL sensitivity, to become the mice-transplanted tumor of knurl in vivo be model, the biological function of checking TRAIL.
The activity of Kininogen D5: in the restraining effect of observation in vitro Kininogen D5 to the newborn endotheliocyte (human umbilical vein, bovine aortic, induced lung source capillary vessel etc.) of cultivation in the presence of alkaline epithelial cell growth factor (bFGF), observe Kininogen D5 in vivo the human colon carcinoma HCT-8 transplanted tumor of chicken embryo bird cyst membrane new vessel growth, the growth of tame rabbit cornea new vessel, nude mice etc. is model, the biological function of checking Kininogen D5.
Concrete test operation is as follows:
1, TRAIL activation analysis: kill and wound various tumour cells
Various target cells derive from cell research institute of the Chinese Academy of Sciences or Shanghai Changhai Hospital.Mainly contain people's pancreas cancerous ductal epithelial cell 1990,8898 strains, the cell lung cancer NCI-460 of the National People's Congress, human colon carcinoma HCT-8, people's cancer of the stomach M85 strain, the SK-N-SH human neuroblastoma cells strain, people's laryngocarcinoma Hep-2 strain, human nasopharyngeal carcinoma CNE-2 strain, human endothelial cell CEV304 strain, human fibroblasts's strain, human colon carcinoma AT-29, human ovarian cancer 3AO, mouse becomes fiber L929 strain, human glioma U251, people's breast cancer, people's liver cancer HepG-2, SMMU7721, human blood is learned tumour (U937, Jukart, HL60 etc.), melanin tumour b16-MB, the Ehrlich ascitic tumor, Lewis sarcoma etc.
With 1990 cells is example, with culturing cell with 2 * 10
8Cell/L kind is gone into 96 porocyte culture plates, 37 ℃ of 5%CO
2Hatched in the incubator 4-6 hour, and abandoned supernatant; Add cell plate after with perfect medium sample being done gradient dilution; Observe to add behind the 1.5 μ g/ml dactinomycins influence simultaneously to various factor killer cell; Activity unit definition: making cell 50% death of cultivating in the plate hole is a unit, tires promptly to reach the dilution inverse of 50% sample when killing and wounding.Do quantitative analysis with the Viola crystallina method: attached cell abandons supernatant, and with Viola crystallina stationary liquid (5g/L Viola crystallina, 80mL/L formaldehyde, 1g/L NaCl, 200mL/L ethanol) dyeing 15 minutes, distilled water flush away Viola crystallina was dried, and the person of being colored is a viable cell.Every hole adds the acetate of 200 μ L 330mL/L again, and the shaking table rotation makes the Viola crystallina dissolving, and put enzyme connection instrument and read the A value in wavelength 595nm, be the A background with the blank well that does not add cell.Suspension cell is determined viable count with mtt assay.Its activity is tired and is done straight-line regression with the mean of the logarithm of diluted sample degree and A595nm, obtains constant A, B, is 50% to kill and wound terminal point (Y) with (A contrast-A background)/2.Calculate the activity unit of sample, i.e. X value by Y=A+BlgX.Simultaneously, this cell is typical apoptosis form under the TRAIL effect, under the effect of 10mg/L Tumor wilting extract, promptly observes cell generation typical change in 2 hours.
2, the cultivation of new born bovine aortic endothelial cell
The about 10cm of clip new born bovine aorta section is long totally two under the aseptic condition; Indoor at aseptic laminar flow, with the aorta trimmed, arterial bifurcation is sentenced the cotton rope ligation; 0.1mol/L PBS with pH7.2 washes aorta lumen, thoroughly removes remaining hemocyte; Pour into about 10ml Digestive system (0.2%II Collagen Type VI enzyme is a solvent with the DMEM substratum) behind cotton rope ligation aorta one end, room temperature leaves standstill digestion 20 minutes; Take out Digestive system,, collect washing fluid and mix, put into aseptic 50ml centrifuge tube with Digestive system with 0.1mol/L PBS flushing aorta inside pipe wall; Centrifugal 10 minutes of 500 * g abandons supernatant; The precipitation (containing cell) 0.1mol/L PBS suspends, centrifugal 10 minutes of 500 * g repeats once; After the DMEM nutrient solution suspension that contains 20%FBS, 200 μ g/ml ECGF, add the plastics Tissue Culture Flask, put 37 ℃, 5%CO
2Cell culture incubator is cultivated; Microscopy has a large amount of cell attachments existence back (needing 3 days approximately) to change liquid, changes liquid once in later per 2 days, treats that the cell growth is individual layer and converges the cultivation of going down to posterity of back routine.
3, the cultivation of induced lung source capillary endothelial cell
The art pre-treatment: get SD rat heavy about 150g, abdominal injection 0.5% heparin sodium aqua 3ml with the stifling anesthetized animal of ether, was dipped in 75% alcohol disinfecting 3 minutes in the sealing cylinder; Lung is got in operation: open chest, cut off left ventricle, right ventricle injection PBS liquid 10ml, flushing lung blood vessel to the left ventricle effluent liquid colourless till, cut lobe of the lung edge, put in the PBS liquid and wash, the lung tissue of cutting is cut into fritter about 2 * 2mm, in the DMEM nutrient solution that contains 20% calf serum, soaked 5 minutes; The fritter lung tissue is placed aseptic, exsiccant plastics Tissue Culture Flask, in 37 ℃, 5%CO
2Cultivated 1.5 hours in the incubator, make the lung tissue piece adherent; Just putting cultivation: the careful DMEM 10ml that contains 20%FBS, 200 μ g/ml ECGF that adds, tissue block is dashed from the bottle wall, put 37 ℃, 5%CO
2Incubator is cultivated; Carefully remove tissue block and change liquid, changed liquid once in later 2 days, cell grows to the cultivation of going down to posterity after individual layer converges.
4. fused protein suppresses various cell proliferation tests
Various cells (mouse source pulmonary capillary endothelial cell, new born bovine aortic endothelial cell, B16 melanoma cell) growth converges back (in the culturing bottle), and with 0.125% trysinization, the DMEM that contains 20%FBS suspends and adjusting cell concn to 5 * 10
4/ ml is inoculated into 96 porocyte culture plates with 100 μ l/ holes, puts 37 ℃, 5%CO
2Incubator is cultivated.Sample is given in the adherent back of inverted phase contrast microscope observation of cell (needing 4～5 hours approximately): the protein initial concentration is 2 μ g/ holes, makes 2 times of gradient dilutions.Put 37 ℃, 5%CO
2Cultivate in the incubator.Add MTT solution 15 μ l/ holes behind the 48h, 37 ℃, 5%CO
2Cultivated 4 hours; Add 100 μ l/ hole mtt assay reaction terminating liquids, put 1h for 37 ℃.With the abundant mixing in each hole and remove the rearmounted enzyme connection of bubble instrument and detect the 595/630nm absorption value.
5. fused protein inhibition of endothelial cell proliferation test
Prepare new born bovine aortic endothelial cell, mouse lung source capillary endothelial cell suspension with preceding method, regulate concentration to 6 * 10
4/ ml is inoculated in the 96 porocyte culture plates with 50 μ l/ holes, puts 37 ℃ of 5%CO
2Incubator is cultivated.(about 4～5 hours) give sample after treating cell attachment: establish six concentration gradients of every hole 0,2.5,5.0,10,20,40 μ l/ml, each concentration gradient is established 10 parallel holes.Add 15 μ l/ hole MTT solution, 37 ℃, 5%CO after 48 hours
2Incubator was cultivated 4 hours.Add 100 μ l/ hole stop buffers, 37 ℃ of temperature were bathed 1 hour.With the abundant mixing in each hole and remove the rearmounted enzyme connection of bubble instrument and detect 595nm/630nm double wave absorption value.Calculate fused protein 50% inhibition concentration.
6. the inhibition test of the new vessel that induces of fusion rotein confrontation rabbit cornea
Sample is coated in a kind of slowly-releasing thing (EVA, promptly ELvax40 is the multipolymer of a kind of ethene and ethene acetate), implants tame rabbit cornea, observe the situation that its inhibition induces angiogenic growth.Sample discharges sustainable release 100 days with the speed of 0.1～1 μ g/d.
50mg EVA was soaked in 75% alcohol 10 minutes, sterilization is placed in the 2ml dichloromethane solution, stirring makes its dissolving, add bacterial endotoxin 8mg and laboratory sample, fully stirring was left standstill its mixing 1 hour in EVA solution, formed the EVA glued membrane, be cut into small pieces, every heavy 1mg, uviolizing 30 minutes, it is standby to sterilize.Rabbit is after intravenous anesthesia (3% vetanarcol, 40 μ g/kg body weight), and 1/3 place makes radial incision (long 2～3mm outside cornea, dark 0.3～0.5mm), with flaggy separator isolated cornea flaggy, make cornea form 3 * 3mm lacuna, insert a treated EVA.Every day observer's rabbit corneal growing state, the 10th day Taking Pictures recording analytical results of postoperative.
7. the inhibition test of fusion rotein confrontation chick chorioallantoic membrane new vessel
It is the same that sample is embedded in EVA, but do not add intracellular toxin.Get instar chicken embryo on the 9th, aseptic dH
2O cleans, and after the 1/4000 formaldehyde wiping, dries, and puts 37 ℃ of incubations.Next day, the chicken embryo to be put under the ovoscopy lamp seek the embryo head, the chorion projection position between the 1cm before distance embryo head, two anterior vitelline veins is with wax crayon 1 * 1.5cm rectangle of drawing.Bore the aperture of about 1.0～2.0mm and penetrate the air chamber shell membrane at the chick embryo air sac end.In the eggshell position of windowing, behind 75% alcohol disinfecting, cut chorion (being sure not to injure the shell membrane of below) along the sideline mill of rectangle with the coil file cutter, clamp rectangle chorion edge with the ophthalmology tweezer, parallelly upwards mention, expose the shell membrane of below, the chorion dust inclines.Follow the shell membrane fiber direction with injection needles and scratch diameter 1mm aperture, can not injure the chorioallantoic membrane (CAM) of below.On the shell membrane window, drip stroke-physiological saline solution a little, dialled the shell membrane of little bore edges then gently with the ophthalmology tweezer, allow between liquid immersion shell membrane and the CAM, treat the CAM sinking after, wipe out rectangular frame endochorion film.The EVA embedded block is directly placed CAM go up avascular area.Seal the ovum window with the sterile transparent adhesive tape, seal the air chamber aperture, hatch for 37 ℃ with paraffin.Remove CAM plane above chorion and shell membrane with the ophthalmology tweezer after three days, note not injuring the CAM blood vessel.On the CAM plane, drip an amount of methyl alcohol, acetone balanced mix stationary liquid, at room temperature fix 15 minutes.After treating that vessel inner blood on the CAM solidifies, the CAM of test zone is cut, place to fill dH
2In the dish ware of O, after the expansion of elbow suction pipe, the dH in the ware that inclines
2O shakeouts CAM at the bottom of ware, upset is affixed on the filter paper Taking Pictures recording result, analytical results.
8. fused protein suppresses mice-transplanted tumor
The amplification of the inside and outside of various tumour cells: the tumour cell recovery back of liquid nitrogen cryopreservation is cultivated or Kunming mouse abdominal cavity (10 is gone in inoculation
7Cell/mouse).Put to death mouse after 10 days, aseptic condition is drawn mouse ascites down, and regulating cell concn with PBS is 10
8/ ml.It is subcutaneous to inoculate sub-experiment mice with this cell suspension 0.2ml.Random packet, every group of 6 mouse, the mouse of subcutaneous vaccination give 0 (PBS, control group), 10,100,1000 μ g (sample)/kg (mouse body weight), administration every other day, 2 weeks respectively.After 1 week of drug withdrawal, put to death mouse, peel off tumour and weigh, calculate every group of heavy and tumour inhibiting rate of average knurl, analytical results.Tumour inhibiting rate calculates with following formula:
Result: the result such as the table 2 of human colon cancer cell HCT-8 transplanted tumor.
Table 2 HCT-8 table with test results
| Protein structure | 10 μ g/kg tumour inhibiting rates (%) | 100 μ g/kg tumour inhibiting rates (%) | 1000 μ g/kg tumour inhibiting rates (%) |
| Fig. 1-A* | ????- | ????- | ????- |
| Fig. 1-B | ????30.8 | ????39.2 | ????44.2 |
| Fig. 1-C | ????25.6 | ????34.9 | ????40.6 |
| Fig. 1-D* | ????- | ????- | ????- |
| Fig. 1-E | ????20.8 | ????31.3 | ????40.5 |
| Fig. 1-F | ????25.6 | ????33.3 | ????41.9 |
| Fig. 1-G* | ????- | ????- | ????- |
| Fig. 1-H | ????33.7 | ????42.6 | ????53.9 |
| Fig. 1-I | ????40.7 | ????49.8 | ????62.6 |
| Fig. 1-a* | ????- | ????- | ????- |
| Fig. 1-b* | ????- | ????- | ????- |
| Fig. 1-c* | ????- | ????- | ????- |
| Fig. 1-d | ????23.5 | ????28.6 | ????36.1 |
| Fig. 1-e | ????22.4 | ????33.6 | ????41.5 |
| Fig. 1-f | ????21.7 | ????34.7 | ????44.8 |
| Fig. 1-g | ????23.8 | ????31.5 | ????45.6 |
| Fig. 1-h | ????29.6 | ????41.7 | ????55.4 |
| Fig. 1-i | ????34.6 | ????47.9 | ????63.4 |
| ?Kininogen?D51-180aa | ????20.6 | ????31.6 | ????37.8 |
| ?TRAIL?114-281aa | ????23.6 | ????36.7 | ????40.9 |
*: not do not measure for these six groups, be because: the Expression of Fusion Protein amount is lower when recombinant expressed, can't obtain a large amount of purifying proteins
By table 2 as seen, recombinant expressed fusion rotein has good inhibitory effect to colon cancer cell.To other transplanted tumors, as the cell lung cancer NCI-H460 of the National People's Congress, human pancreas cancer SW1990,8898 strains, people's cancer of the stomach M85, people's laryngocarcinoma Hep-2, human nasopharyngeal carcinoma CNE-2, human colon carcinoma AT-29, human glioma U251, people's liver cancer HepG-2, melanin tumour b16-MB, the Ehrlich ascitic tumor can be obtained similar result on the models such as Lewis sarcoma.
All quote in this application as a reference at all documents that the present invention mentions, just quoted as a reference separately as each piece document.Should be understood that in addition those skilled in the art can make various changes or modifications the present invention after having read above-mentioned teachings of the present invention, these equivalent form of values fall within the application's appended claims institute restricted portion equally.
Sequence table
＜110〉Second Military Medical University, PLA
＜120〉fusion rotein of prokinin the 5th structural domain-tumor necrosin relative death inducing ligand and method for making thereof and purposes
<130>
<160>37
<170>Patent?In?version?3.1
<210>1
<211>801
<212>DNA
＜213〉homo sapiens (Homo sapiens)
<400>1
atgaaaaggc?ctccaggttt?ttcacctttc?cgatcatcac?gaatagggga?aataaaagaa?????60
gaaacaactg?taagtccacc?ccacacttcc?atggcacctg?cacaagatga?agagcgggat????120
tcaggaaaag?aacaagggca?tactcgtaga?catgactggg?gccatgaaaa?acaaagaaaa????180
cataatcttg?gccatggcca?taaacatgaa?cgtgaccaag?ggcatgggca?ccaaagagga????240
catggccttg?gccatggaca?cgaacaacag?catggtcttg?gtcatggaca?taagttcaaa????300
cttgatgatg?atcttgaaca?ccaagggggc?catgtccttg?accatggaca?taagcataag????360
catggtcatg?gccacggaaa?acataaaaat?aaaggcaaaa?agaatggaaa?gcacaatggt????420
tggaaaacag?agcatttggc?aagctcttct?gaagacagta?ctacaccttc?tgcacagaca????480
caagagaaga?cagaagggcc?aacacccatc?ccttccctag?ccaagccagg?tgtaacagtt????540
accttttctg?actttcagga?ctctgatctc?attgcaacta?tgatgcctcc?tatatcacca????600
gctcccatac?agagtgatga?cgattggatc?cctgatatcc?agatagaccc?aaatggcctt????660
tcatttaacc?caatatcaga?ttttccagac?acgacctccc?caaaatgtcc?tggacgcccc????720
tggaagtcag?ttagtgaaat?taatccaacc?acacaaatga?aagaatctta?ttatttcgat????780
ctcactgatg?gcctttctta?a??????????????????????????????????????????????801
<210>2
<211>417
<212>PRT
＜213〉homo sapiens (Homo sapiens)
<400>2
Met?Lys?Arg?Pro?Pro?Gly?Phe?Ser?Pro?Phe?Arg?Ser?Ser?Arg?Ile?Gly
1???????????????5??????????????????10???????????????????15
Glu?Ile?Lys?Glu?Glu?Thr?Thr?Val?Ser?Pro?Pro?His?Thr?Ser?Met?Ala
20?????????????????25???????????????????30
Pro?Ala?Gln?Asp?Glu?Glu?Arg?Asp?Ser?Gly?Lys?Glu?Gln?Gly?His?Thr
35?????????????????40??????????????????45
Arg?Arg?His?Asp?Trp?Gly?His?Glu?Lys?Gln?Arg?Lys?His?Asn?Leu?Gly
50?????????????????55??????????????????60
His?Gly?His?Lys?His?Glu?Arg?Asp?Gln?Gly?His?Gly?His?Gln?Arg?Gly
65?????????????????70??????????????????75??????????????????80
His?Gly?Leu?Gly?His?Gly?His?Glu?Gln?Gln?His?Gly?Leu?Gly?His?Gly
85?????????????????90??????????????????95
His?Lys?Phe?Lys?Leu?Asp?Asp?Asp?Leu?Glu?His?Gln?Gly?Gly?His?Val
100????????????????105?????????????????110
Leu?Asp?His?Gly?His?Lys?His?Lys?His?Gly?His?Gly?His?Gly?Lys?His
115????????????????120?????????????????125
Lys?Asn?Lys?Gly?Lys?Lys?Asn?Gly?Lys?His?Asn?Gly?Trp?Lys?Thr?Glu
130????????????????135?????????????????140
His?Leu?Ala?Ser?Ser?Ser?Glu?Asp?Ser?Thr?Thr?Pro?Ser?Ala?Gln?Thr
145?????????????????150????????????????155?????????????????160
Gln?Glu?Lys?Thr?Glu?Gly?Pro?Thr?Pro?Ile?Pro?Ser?Leu?Ala?Lys?Pro
165????????????????170?????????????????175
Gly?Val?Thr?Val?Thr?Phe?Ser?Asp?Phe?Gln?Asp?Ser?Asp?Leu?Ile?Ala
180????????????????185?????????????????190
Thr?Met?Met?Pro?Pro?Ile?Ser?Pro?Ala?Pro?Ile?Gln?Ser?Asp?Asp?Asp
195????????????????200?????????????????205
Trp?Ile?Pro?Asp?Ile?Gln?Ile?Asp?Pro?Asn?Gly?Leu?Ser?Phe?Asn?Pro
210????????????????215?????????????????220
Ile?Ser?Asp?Phe?Pro?Asp?Thr?Thr?Ser?Pro?Lys?Cys?Pro?Gly?Arg?Pro
225????????????????230?????????????????235?????????????????240
Trp?Lys?Ser?Val?Ser?Glu?Ile?Asn?Pro?Thr?Thr?Gln?Met?Lys?Glu?Ser
245?????????????????250?????????????????255
Tyr?Tyr?Phe?Asp?Leu?Thr?Asp?Gly?Leu?Ser
260????????????????265
<210>3
<211>846
<212>DNA
＜213〉homo sapiens (Homo sapiens)
<400>3
atggctatga?tggaggtcca?ggggggaccc?agcctgggac?agacctgcgt?gctgatcgtg?????60
atcttcacag?tgctcctgca?gtctctctgt?gtggctgtaa?cttacgtgta?ctttaccaac????120
gagctgaagc?agatgcagga?caagtactcc?aaaagtggca?ttgcttgttt?cttaaaagaa????180
gatgacagtt?attgggaccc?caatgacgaa?gagagtatga?acagcccctg?ctggcaagtc????240
aagtggcaac?tccgtcagct?cgttagaaag?atgattttga?gaacctctga?ggaaaccatt????300
tctacagttc?aagaaaagca?acaaaatatt?tctcccctag?tgagagaaag?aggtcctcag????360
agagtagcag?ctcacataac?tgggaccaga?ggaagaagca?acacattgtc?ttctccaaac????420
tccaagaatg?aaaaggctct?gggccgcaaa?ataaactcct?gggaatcatc?aaggagtggg????480
cattcattcc?tgagcaactt?gcacttgagg?aatggtgaac?tggtcatcca?tgaaaaaggg????540
ttttactaca?tctattccca?aacatacttt?cgatttcagg?aggaaataaa?agaaaacaca????600
aagaacgaca?aacaaatggt?ccaatatatt?tacaaataca?caagttatcc?tgaccctata????660
ttgttgatga?aaagtgctag?aaatagttgt?tggtctaaag?atgcagaata?tggactctat????720
tccatctatc?aagggggaat?atttgagctt?aaggaaaatg?acagaatttt?tgtttctgta????780
acaaatgagc?acttgataga?catggaccat?gaagccagtt?ttttcggggc?ctttttagtt????840
ggctaa???????????????????????????????????????????????????????????????846
<210>4
<211>281
<212>PRT
＜213〉homo sapiens (Homo sapiens)
<400>4
Met?Ala?Met?Met?Glu?Val?Gln?Gly?Gly?Pro?Ser?Leu?Gly?Gln?Thr?Cys
1??????????????5???????????????????10??????????????????15
Val?Leu?Ile?Val?Ile?Phe?Thr?Val?Leu?Leu?Gln?Ser?Leu?Cys?Val?Ala
20??????????????????25??????????????????30
Val?Thr?Tyr?Val?Tyr?Phe?Thr?Asn?Glu?Leu?Lys?Gln?Met?Gln?Asp?Lys
35?????????????????40??????????????????45
Tyr?Ser?Lys?Ser?Gly?Ile?Ala?Cys?Phe?Leu?Lys?Glu?Asp?Asp?Ser?Tyr
50?????????????????55??????????????????60
Trp?Asp?Pro?Asn?Asp?Glu?Glu?Ser?Met?Asn?Ser?Pro?Cys?Trp?Gln?Val
65?????????????????70??????????????????75??????????????????80
Lys?Trp?Gln?Leu?Arg?Gln?Leu?Val?Arg?Lys?Met?Ile?Leu?Arg?Thr?Ser
85??????????????????90??????????????????95
Glu?Glu?Thr?Ile?Ser?Thr?Val?Gln?Glu?Lys?Gln?Gln?Asn?Ile?Ser?Pro
100????????????????105?????????????????110
Leu?Val?Arg?Glu?Arg?Gly?Pro?Gln?Arg?Val?Ala?Ala?His?Ile?Thr?Gly
115????????????????120?????????????????125
Thr?Arg?Gly?Arg?Ser?Asn?Thr?Leu?Ser?Ser?Pro?Asn?Ser?Lys?Asn?Glu
130????????????????135????????????????140
Lys?Ala?Leu?Gly?Arg?Lys?Ile?Asn?Ser?Trp?Glu?Ser?Ser?Arg?Ser?Gly
145?????????????????150????????????????155?????????????????160
His?Ser?Phe?Leu?Ser?Asn?Leu?His?Leu?Arg?Asn?Gly?Glu?Leu?Val?Ile
165????????????????170?????????????????175
His?Glu?Lys?Gly?Phe?Tyr?Tyr?Ile?Tyr?Ser?Gln?Thr?Tyr?Phe?Arg?Phe
180????????????????185?????????????????190
Gln?Glu?Glu?Ile?Lys?Glu?Asn?Thr?Lys?Asn?Asp?Lys?Gln?Met?Val?Gln
195????????????????200?????????????????205
Tyr?Ile?Tyr?Lys?Tyr?Thr?Ser?Tyr?Pro?Asp?Pro?Ile?Leu?Leu?Met?Lys
210????????????????215?????????????????220
Ser?Ala?Arg?Asn?Ser?Cys?Trp?Ser?Lys?Asp?Ala?Glu?Tyr?Gly?Leu?Tyr
225????????????????230?????????????????235?????????????????240
Ser?Ile?Tyr?Gln?Gly?Gly?Ile?Phe?Glu?Leu?Lys?Glu?Asn?Asp?Arg?Ile
245????????????????250?????????????????255
Phe?Val?Ser?Val?Thr?Asn?Glu?His?Leu?Ile?Asp?Met?Asp?His?Glu?Ala
260????????????????265?????????????????270
Ser?Phe?Phe?Gly?Ala?Phe?Leu?Val?Gly
275????????????????280
<210>5
<211>819
<212>DNA
＜213〉artificial sequence
<220>
<221>misc_feature
<222>(1)..(819)
＜223〉fusion rotein encoding sequence
<400>5
atgaaacata?atcttggcca?tggccataaa?catgaacgtg?accaagggca?tgggcaccaa?????60
agaggacatg?gccttggcca?tggacacgaa?caacagcatg?gtcttggtca?tggacataag????120
ttcaaacttg?atgatgatct?tgaacaccaa?gggggccatg?tccttgacca?tggacataag????180
cataagcatg?gtcatggcca?cggaaaacat?aaaaataaag?gcaaaaagaa?tggaaagcac????240
aatggttgga?aaacagagca?tttggcaagc?ggatccggcg?gaggcgggag?cggcgggggc????300
ggaagcctgc?aggtgagaga?aagaggtcct?cagagagtag?cagctcacat?aactgggacc????360
agaggaagaa?gcaacacatt?gtcttctcca?aactccaaga?atgaaaaggc?tctgggccgc????420
aaaataaact?cctgggaatc?atcaaggagt?gggcattcat?tcctgagcaa?cttgcacttg????480
aggaatggtg?aactggtcat?ccatgaaaaa?gggttttact?acatctattc?ccaaacatac????540
tttcgatttc?aggaggaaat?aaaagaaaac?acaaagaacg?acaaacaaat?ggtccaatat????600
atttacaaat?acacaagtta?tcctgaccct?atattgttga?tgaaaagtgc?tagaaatagt????660
tgttggtcta?aagatgcaga?atatggactc?tattccatct?atcaaggggg?aatatttgag????720
cttaaggaaa?atgacagaat?ttttgtttct?gtaacaaatg?agcacttgat?agacatggac????780
catgaagcca?gttttttcgg?ggccttttta?gttggctaa???????????????????????????819
<210>6
<211>272
<212>PRT
＜213〉artificial sequence
<220>
<221>MISC_FEATURE
＜223〉fusion rotein
<400>6
Met?Lys?His?Asn?Leu?Gly?His?Gly?His?Lys?His?Glu?Arg?Asp?Gln?Gly
1???????????????5??????????????????10??????????????????15
His?Gly?His?Gln?Arg?Gly?His?Gly?Leu?Gly?His?Gly?His?Glu?Gln?Gln
20??????????????????25??????????????????30
His?Gly?Leu?Gly?His?Gly?His?Lys?Phe?Lys?Leu?Asp?Asp?Asp?Leu?Glu
35?????????????????40??????????????????45
His?Gln?Gly?Gly?His?Val?Leu?Asp?His?Gly?His?Lys?His?Lys?His?Gly
50?????????????????55??????????????????60
His?Gly?His?Gly?Lys?His?Lys?Asn?Lys?Gly?Lys?Lys?Asn?Gly?Lys?His
65?????????????????70??????????????????75??????????????????80
Asn?Gly?Trp?Lys?Thr?Glu?His?Leu?Ala?Ser?Gly?Ser?Gly?Gly?Gly?Gly
85??????????????????90??????????????????95
Ser?Gly?Gly?Gly?Gly?Ser?Leu?Gln?Val?Arg?Glu?Arg?Gly?Pro?Gln?Arg
100????????????????105?????????????????110
Val?Ala?Ala?His?Ile?Thr?Gly?Thr?Arg?Gly?Arg?Ser?Asn?Thr?Leu?Ser
115????????????????120?????????????????125
Ser?Pro?Asn?Ser?Lys?Asn?Glu?Lys?Ala?Leu?Gly?Arg?Lys?Ile?Asn?Ser
130????????????????135?????????????????140
Trp?Glu?Ser?Ser?Arg?Ser?Gly?His?Ser?Phe?Leu?Ser?Asn?Leu?His?Leu
145?????????????????150????????????????155?????????????????160
Arg?Asn?Gly?Glu?Leu?Val?Ile?His?Glu?Lys?Gly?Phe?Tyr?Tyr?Ile?Tyr
165????????????????170?????????????????175
Ser?Gln?Thr?Tyr?Phe?Arg?Phe?Gln?Glu?Glu?Ile?Lys?Glu?Asn?Thr?Lys
180????????????????185?????????????????190
Asn?Asp?Lys?Gln?Met?Val?Gln?Tyr?Ile?Tyr?Lys?Tyr?Thr?Ser?Tyr?Pro
195????????????????200?????????????????205
Asp?Pro?Ile?Leu?Leu?Met?Lys?Ser?Ala?Arg?Asn?Ser?Cys?Trp?Ser?Lys
210????????????????215?????????????????220
Asp?Ala?Glu?Tyr?Gly?Leu?Tyr?Ser?Ile?Tyr?Gln?Gly?Gly?Ile?Phe?Glu
225????????????????230?????????????????235?????????????????240
Leu?Lys?Glu?Asn?Asp?Arg?Ile?Phe?Val?Ser?Val?Thr?Asn?Glu?His?Leu
245????????????????250?????????????????255
Ile?Asp?Met?Asp?His?Glu?Ala?Ser?Phe?Phe?Gly?Ala?Phe?Leu?Val?Gly
260????????????????265?????????????????270
<210>7
<211>1288
<212>DNA
＜213〉artificial sequence
<220>
<221>misc_feature
<222>(1)..(1288)
＜223〉the feature nucleotide sequence of pBV-TRAIL
<400>7
aaattcttca?acgctaactt?tgagaatttt?tgtaagcaat?gcggcgttat?aagcatttaa??????60
tgcattgatg?ccattaaata?aagcaccaac?gcctgactgc?cccatcccca?tcttgtctgc?????120
acgtgcgtcc?tcaagctgct?cttgtgttaa?tggtttcttt?tttgtgctca?tacgttaaat?????180
ctatcaccgc?aagggataaa?tatctaacac?cgtgcgtgtt?gactatttta?cctctggcgg?????240
tgataatggt?tgcatgtact?aaggaggttg?tatggaacaa?cgcataaccc?tgaaagatta?????300
tgcaatgcgc?tttgggcaaa?ccaagacagc?taaagatctc?tcacctacca?aacaatgccc?????360
ccctgcaaaa?aataaattca?tataaaaaac?atacagataa?ccatctgcgg?tgataaatta?????420
tctctggcgg?tgttgacata?aataccactg?gcggtgatac?tgagcacatc?agcaggacgc?????480
actgaccacc?atgaaggtga?cgctcttaaa?aattaagccc?tgaagaaggg?cagcattcaa?????540
agcagaaggc?tttggggtgt?gtgatacgaa?acgaagcatt?ggttaaaaat?taaggaggaa?????600
ttcacaatgg?tgagagaaag?aggtcctcag?agagtagcag?ctcacataac?tgggaccaga?????660
ggaagaagca?acacattgtc?ttctccaaac?tccaagaatg?aaaaggctct?gggccgcaaa?????720
ataaactcct?gggaatcatc?aaggagtggg?cattcattcc?tgagcaactt?gcacttgagg?????780
aatggtgaac?tggtcatcca?tgaaaaaggg?ttttactaca?tctattccca?aacatacttt?????840
cgatttcagg?aggaaataaa?agaaaacaca?aagaacgaca?aacaaatggt?ccaatatatt?????900
tacaaataca?caagttatcc?tgaccctata?ttgttgatga?aaagtgctag?aaatagttgt?????960
tggtctaaag?atgcagaata?tggactctat?tccatctatc?aagggggaat?atttgagctt????1020
aaggaaaatg?acagaatttt?tgtttctgta?acaaatgagc?acttgataga?catggaccat????1080
gaagccagtt?tttttggggc?ctttttagtt?ggctaaggat?ccgtcgacct?gcagccaagc????1140
ttggctgttt?tggcggatga?gagaagattt?tcagcctgat?acagattaaa?tcagaacgca????1200
gaagcggtct?gataaaacag?aatttgcctg?gcggcagtag?cgcgggtggt?cccacctgac????1260
cccatgccga?actcagaagt?gaaacccc???????????????????????????????????????1288
<210>8
<211>29
<212>DNA
＜213〉artificial sequence
<400>8
gcgaattcac?atatgaaaag?gcctccagg?????????????????????????????????29
<210>9
<211>28
<212>DNA
＜213〉artificial sequence
<400>9
gcgaattcat?ggtaagtcca?ccccacac??????????????????????????????????28
<210>10
<211>33
<212>DNA
＜213〉artificial sequence
<400>10
gcgaattc?atgaaacat?aatcttggcc?atg???????????????????????????????33
<210>11
<211>26
<212>DNA
＜213〉artificial sequence
<400>11
aaggatccgc?ttgccaaat?gctctg?????????????????????????????????????26
<210>12
<211>28
<212>DNA
＜213〉artificial sequence
<400>12
aaggatccac?tgtcttcaga?agagcttg??????????????????????????????????28
<210>13
<211>26
<212>DNA
＜213〉artificial sequence
<400>13
aaggatccag?aaaggccatc?agtgag????????????????????????????????????26
<210>14
<211>26
<212>DNA
＜213〉artificial sequence
<400>14
aactgcagat?ggctatgatg?gaggtc???????????????????????????????26
<210>15
<211>26
<212>DNA
＜213〉artificial sequence
<400>15
aactgcagac?ctctgaggaa?accatt???????????????????????????????26
<210>16
<211>27
<212>DNA
＜213〉artificial sequence
<400>16
aactgcaggt?gagagaaaga?ggtcctc??????????????????????????????27
<210>17
<211>24
<212>DNA
＜213〉artificial sequence
<400>17
tcaagcttag?ccaactaaaa?aggc?????????????????????????????????24
<210>18
<211>30
<212>DNA
＜213〉artificial sequence
<400>18
gcgaattcac?atatggctat?gatggaggtc???????????????????????????30
<210>19
<211>33
<212>DNA
＜213〉artificial sequence
<400>19
gcgaattcaca?tatgacctc?tgaggaaacc?att???????????????????????33
<210>20
<211>29
<212>DNA
＜213〉artificial sequence
<400>20
gcgaattcaca?tatggtgag?agaaagagg????????????????????????????29
<210>21
<211>24
<212>DNA
＜213〉artificial sequence
<400>21
aaggatccaa?ctaaaaaggc?cccg????????????????????????????24
<210>22
<211>25
<212>DNA
＜213〉artificial sequence
<400>22
aactgcagat?gaaaaggcct?ccagg???????????????????????????25
<210>23
<211>25
<212>DNA
＜213〉artificial sequence
<400>23
aactgcaggta?agtccaccc?cacac???????????????????????????25
<210>24
<211>27
<212>DNA
＜213〉artificial sequence
<400>24
tcaagcttag?cttgccaaa?tgctctg??????????????????????????27
<210>25
<211>32
<212>DNA
＜213〉artificial sequence
<400>25
aactgcagaa?acataatctt?ggccatg?????????????????????????27
<210>26
<211>29
<212>DNA
＜213〉artificial sequence
<400>26
Tcaagcttaa?ctgtcttcag?aagagcttg???????????????????????29
<210>27
<211>25
<212>DNA
＜213〉artificial sequence
<400>27
tcaagcttaa?gaaaggccat?cagtg???????????????????????????25
<210>28
<211>40
<212>DNA
＜213〉artificial sequence
<400>28
gatccggcgg?aggcgggagc?ggcgggggcg?gaagcctgca????????????????????????40
<210>29
<211>32
<212>DNA
＜213〉artificial sequence
<400>29
ggcttccgcc?cccgccgctc?ccgcctccgc?cg????????????????????????????????32
<210>30
<211>21
<212>DNA
＜213〉artificial sequence
<400>30
ttttaaaggg?cccgcgcgtt?g????????????????????????????????????????????21
<210>31
<211>21
<212>DNA
＜213〉artificial sequence
<400>31
atttggcgcg?gcaagctcag?c????????????????????????????????????????????21
<210>32
<211>24
<212>DNA
＜213〉artificial sequence
<400>32
gacttacagc?agtcagactc?tgac?????????????????????????????????????????24
<210>33
<211>24
<212>DNA
＜213〉artificial sequence
<400>33
tattgctttt?tctttccagg?tcag?????????????????????????????????????????24
<210>34
<211>30
<212>DNA
＜213〉artificial sequence
<400>34
acgaattcac?aatggtgaga?gaaagaggtc???????????????????????????????????????30
<210>35
<211>24
<212>DNA
＜213〉artificial sequence
<400>35
acggatcctt?agccaactaa?aaag?????????????????????????????????????????????24
<210>36
<211>274
<212>DNA
＜213〉artificial sequence
<400>36
aaagatctct?cacctaccaa?acaatgcccc?cctgcaaaaa?ataaattcat?ataaaaaaca??????60
tacagataac?catctgcggt?gataaattat?ctctggcggt?gttgacataa?ataccactgg?????120
cggtgatact?gagcacatca?gcaggacgca?ctgaccacca?tgaaggtgac?gctcttaaaa?????180
attaagccct?gaagaagggc?agcattcaaa?gcagaaggct?ttggggtgtg?tgatacgaaa?????240
cgaagcattg?gttaaaaatt?aaggaggaat?tcaca????????????????????????????????274
<210>37
<211>60
<212>DNA
＜213〉artificial sequence
<400>37
aaggatccgt?cgacctgcag?ccaagcttgg?ctgttttggc?ggatgagaga?agattttcag??????60
Claims (10)
1. fused protein is characterized in that it comprises:
(a) prokinin the 5th structural domain element, this element has the aminoacid sequence of people's prokinin the 5th structural domain or its active fragments;
(b) tumor necrosin relative death inducing ligand element, this element has the aminoacid sequence of apoptosis induction ligand related to human tumor necrosis factor or its active fragments; And
(c) 1-20 between prokinin the 5th structural domain element and tumor necrosin relative death inducing ligand element amino acid whose catenation sequence.
2. fusion rotein as claimed in claim 1 is characterized in that, described prokinin the 5th structural domain element has the aminoacid sequence of 1-266 position, 24-153 position or 60-148 position among the SEQ ID NO.2;
Described tumor necrosin relative death inducing ligand element has the aminoacid sequence of 1-281 position, 95-281 position, 114-281 position among the SEQ ID NO.4;
And described joint peptide sequence contains 4-10 amino acid.
3. fusion rotein as claimed in claim 1 is characterized in that described fusion rotein comprises the aminoacid sequence shown in the SEQ IDNO.6.
4. an isolated DNA molecule is characterized in that, the described fused protein of its coding claim 1.
5. dna molecular as claimed in claim 4 is characterized in that, it comprises the nucleotide sequence shown in the SEQ ID NO.5.
6. a carrier is characterized in that, it contains the described dna molecular of claim 4.
7. a host cell is characterized in that, it contains the described carrier of claim 6.
8. method that produces the described fusion rotein of claim 1 is characterized in that it comprises step:
Being fit to express under the condition of described fusion rotein, cultivate the described host cell of claim 7, thereby give expression to described fusion rotein; With separate described fusion rotein.
9. a pharmaceutical composition is characterized in that, comprises pharmaceutically acceptable carrier or vehicle or thinner, and the described fusion rotein of the claim 1 of significant quantity.
10. the purposes of the described fusion rotein of claim 1 is characterized in that, is used to prepare the medicine for the treatment of tumour.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200310109265 CN1256347C (en) | 2003-12-10 | 2003-12-10 | Fusion protein of kininogen D5 and tumor necrosis factor related apoptosis-inducing ligand(D5-TRAIL), its preparation and use thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200310109265 CN1256347C (en) | 2003-12-10 | 2003-12-10 | Fusion protein of kininogen D5 and tumor necrosis factor related apoptosis-inducing ligand(D5-TRAIL), its preparation and use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1546528A true CN1546528A (en) | 2004-11-17 |
| CN1256347C CN1256347C (en) | 2006-05-17 |
Family
ID=34335103
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200310109265 Expired - Fee Related CN1256347C (en) | 2003-12-10 | 2003-12-10 | Fusion protein of kininogen D5 and tumor necrosis factor related apoptosis-inducing ligand(D5-TRAIL), its preparation and use thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1256347C (en) |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101456913B (en) * | 2008-10-14 | 2011-06-08 | 浙江大学 | Anti-tumor fusion protein and use thereof |
| CN102206281A (en) * | 2011-03-28 | 2011-10-05 | 中国人民解放军第三军医大学第一附属医院 | Fusion protein TETPH, expression vector and construction method thereof |
| WO2012093158A1 (en) * | 2011-01-05 | 2012-07-12 | Adamed Sp. Z O.O. | Anticancer fusion protein |
| CN102775491A (en) * | 2011-05-09 | 2012-11-14 | 中国人民解放军第二军医大学 | Preparation method and application of single-chain human apoptosis-2 ligand (Apo2L) trimer protein |
| CN102958940A (en) * | 2010-06-25 | 2013-03-06 | 阿达梅德公司 | Anticancer fusion protein |
| WO2013098755A3 (en) * | 2011-12-28 | 2013-08-29 | Adamed Sp. Z O.O. | Anticancer fusion protein |
| CN104672327A (en) * | 2015-02-02 | 2015-06-03 | 首都医科大学附属北京天坛医院 | Protein, gene encoding protein and antitumor application and applications of gene as antitumor drug assistant medicament |
| CN104177500B (en) * | 2013-05-24 | 2018-05-25 | 江苏靶标生物医药研究所有限公司 | A kind of tumour putrescence gene related apoptosis ligand fusion protein and its preparation method and purposes |
| TWI685351B (en) * | 2016-12-29 | 2020-02-21 | 財團法人生物技術開發中心 | Peptides derived from kininogen-1 for protein drugs in vivo half-life extensions |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL394618A1 (en) | 2011-04-19 | 2012-10-22 | Adamed Spólka Z Ograniczona Odpowiedzialnoscia | Anticancer fusion protein |
-
2003
- 2003-12-10 CN CN 200310109265 patent/CN1256347C/en not_active Expired - Fee Related
Cited By (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101456913B (en) * | 2008-10-14 | 2011-06-08 | 浙江大学 | Anti-tumor fusion protein and use thereof |
| CN102958940B (en) * | 2010-06-25 | 2015-12-02 | 阿达梅德公司 | Anticancer fusion protein |
| CN102958940A (en) * | 2010-06-25 | 2013-03-06 | 阿达梅德公司 | Anticancer fusion protein |
| EA025830B1 (en) * | 2011-01-05 | 2017-02-28 | Адамед Сп. З О.О. | Anticancer fusion protein |
| CN103228788B (en) * | 2011-01-05 | 2016-09-07 | 阿达梅德公司 | Anticancer fusion protein |
| WO2012093158A1 (en) * | 2011-01-05 | 2012-07-12 | Adamed Sp. Z O.O. | Anticancer fusion protein |
| CN103228788A (en) * | 2011-01-05 | 2013-07-31 | 阿达梅德公司 | Anticancer fusion protein |
| JP2014504868A (en) * | 2011-01-05 | 2014-02-27 | アダムド エスピー．ゼット オー．オー． | Anticancer fusion protein |
| US9175059B2 (en) | 2011-01-05 | 2015-11-03 | Adamed Sp. Z O.O. | Anticancer fusion protein comprising trail and a growth factor receptor inhibitor |
| AU2012204900B2 (en) * | 2011-01-05 | 2014-12-18 | Adamed Sp. Z O.O. | Anticancer fusion protein |
| CN102206281B (en) * | 2011-03-28 | 2014-04-09 | 中国人民解放军第三军医大学第一附属医院 | Fusion protein TETPH, expression vector and construction method thereof |
| CN102206281A (en) * | 2011-03-28 | 2011-10-05 | 中国人民解放军第三军医大学第一附属医院 | Fusion protein TETPH, expression vector and construction method thereof |
| CN102775491A (en) * | 2011-05-09 | 2012-11-14 | 中国人民解放军第二军医大学 | Preparation method and application of single-chain human apoptosis-2 ligand (Apo2L) trimer protein |
| WO2013098755A3 (en) * | 2011-12-28 | 2013-08-29 | Adamed Sp. Z O.O. | Anticancer fusion protein |
| CN104177500B (en) * | 2013-05-24 | 2018-05-25 | 江苏靶标生物医药研究所有限公司 | A kind of tumour putrescence gene related apoptosis ligand fusion protein and its preparation method and purposes |
| CN104672327A (en) * | 2015-02-02 | 2015-06-03 | 首都医科大学附属北京天坛医院 | Protein, gene encoding protein and antitumor application and applications of gene as antitumor drug assistant medicament |
| CN104672327B (en) * | 2015-02-02 | 2019-03-22 | 首都医科大学附属北京天坛医院 | A kind of protein and the gene for encoding the protein, are used for anti-tumor application and the application as anti-tumor drug assistant medicament |
| TWI685351B (en) * | 2016-12-29 | 2020-02-21 | 財團法人生物技術開發中心 | Peptides derived from kininogen-1 for protein drugs in vivo half-life extensions |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1256347C (en) | 2006-05-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1515672A (en) | Human chemotactic factor beta-8, chemotactic factor beta-1 and macrophage inflammatory protein-4 | |
| CN101045156A (en) | Special target medicine and its use | |
| CN1764723A (en) | Interleukin-18 mutants, their production and use | |
| CN1256347C (en) | Fusion protein of kininogen D5 and tumor necrosis factor related apoptosis-inducing ligand(D5-TRAIL), its preparation and use thereof | |
| CN101062954A (en) | Fusion protein having blood vessel formation against function and its coding gene and application | |
| CN1568369A (en) | Hybrid interferon/interferon Tau proteins, compositions and methods of use | |
| CN1161468C (en) | MPL ligand analogs | |
| CN1257187C (en) | Calreticulin-tumor necrosis factor correlated apoptosis inducing ligand fusion protein and its prepn and use | |
| CN1760205A (en) | Mutant of ciliary nerves trophic factor (CNTF), producing method and usage | |
| CN1187447C (en) | MPL ligand analogs | |
| CN1283793C (en) | Chemokine-like factor superfamily having skeletal muscle stimulating activity and immunoregulation function | |
| CN1684979A (en) | Glycosylated human interferon alpha isoform | |
| CN1629194A (en) | Super antigen fusion protein for cancer therapy and its producing method | |
| CN1781933A (en) | Thymosin alpha 1 active segment cyclicpeptide analogue and its poly glycol derivative | |
| CN101062955A (en) | Fusion protein having inhibitory action on tumour cell and its coding gene and application | |
| CN1286973C (en) | Histone methyl transferase and its preparing method | |
| CN1626554A (en) | Interfusion protein between human serum albumin and interleukin, and encoding genes | |
| CN1170850C (en) | Human angiogenin-like protein and coding sequence and application thereof | |
| CN101050238A (en) | Interfusion protein between diphtheria toxin and GM CSF mutant, coded gene and application | |
| CN1200097C (en) | Recombinant human epidermal growth factor and its preparing process and medicinal composition | |
| CN1100957A (en) | Recombinant product | |
| CN1244375C (en) | Human liver regeneration related protein and its application | |
| CN1186448C (en) | Recombinant human alpha-prothymosin interleukin 2 gene and its expression and use | |
| CN1621411A (en) | Recombinant targeted fusion protein for treating acquired immunodeficiency syndrome | |
| CN1168739C (en) | Narcissus seed glycopeptide and its application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |